699 results on '"Mougiakakos, Dimitrios"'
Search Results
102. CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints
103. Feasibility, Safety, and Preliminary Efficacy of Very Low-Volume Interval Training in Advanced Cancer Patients
104. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia
105. CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours.
106. CD4+ T cell-induced inflammatory killing controls immune evasive tumours
107. Mitochondrial respiration in B lymphocytes is essential for humoral immunity by controlling the flux of the TCA cycle
108. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
109. Genetic Knock-out of TNFR1 and TNFR2 in a JAK2-V617F Polycythemia Vera Mouse Model
110. Anticancer Aminoferrocene Derivatives Inducing Production of Mitochondrial Reactive Oxygen Species
111. Anti-CD37 CAR T cells: another arrow in the quiver
112. CAR T-cell perspectives in lupus – Authors' reply
113. Prognostic Impact of Quality and Distribution of Adipose Tissue in Patients With Primary Central Nervous System Lymphoma
114. CD4+T cell-induced inflammatory cell death controls immune-evasive tumours
115. Impact of FLT3-ITDlocation on cytarabine sensitivity in AML: a network-based approach
116. The impact of inflammatory licensing on heme oxygenase-1–mediated induction of regulatory T cells by human mesenchymal stem cells
117. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
118. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
119. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis
120. The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL
121. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis
122. IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation
123. T-Cell Metabolism in Graft Versus Host Disease
124. Rapid and Efficient Gene Editing for Direct Transplantation of Naive Murine Cas9+ T Cells
125. Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany
126. Pleiotropic effects of antibiotics on Tcell metabolism and T cell-mediated immunity.
127. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
128. β2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression
129. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
130. Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
131. JAK2-V617F Promotes up-Regulation of Pro-Inflammatory Cytokines Including IL-1 upon Adhesion-Induced Activation of β1/β2 Integrins
132. The complement system drives local inflammatory tissue priming by metabolic reprogramming of synovial fibroblasts
133. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis
134. High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosis
135. Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
136. Linking Immunoevasion and Metabolic Reprogramming in B-Cell–Derived Lymphomas
137. Camouflage and sabotage: tumor escape from the immune system
138. Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
139. Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9highAML cell subset
140. The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages
141. Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells
142. Mitochondrial function is essential for humoral immunity by controlling flux of the TCA cycle, phosphatidic acid and mTOR activity in B cells
143. β 2-Microglobulin - A Trigger for NLRP3 Inflammasome Activation in Tumor-Associated Macrophages Promoting Multiple Myeloma Progression
144. The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation
145. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
146. Regulatory T Cells in Cancer
147. Chapter 6 Oxidative Stress and Lymphocyte Persistence
148. Nuclear HER3 is associated with favorable overall survival in uveal melanoma
149. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
150. Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.